{"id":271,"date":"2015-04-28T08:43:15","date_gmt":"2015-04-28T08:43:15","guid":{"rendered":"http:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=271"},"modified":"2015-04-28T08:43:15","modified_gmt":"2015-04-28T08:43:15","slug":"nota-informativa-muh-fv-62015","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2015\/04\/28\/nota-informativa-muh-fv-62015\/","title":{"rendered":"Nota Informativa MUH (FV), 6\/2015"},"content":{"rendered":"<p><a href=\"http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2015\/NI-MUH_FV_06-antivirales-VHC-amiodarona.htm\">Riesgo de bradicardia severa y bloqueo cardiaco asociado a la administraci\u00f3n de \u25bcHarvoni\u00ae, y la combinaci\u00f3n de \u25bcSovaldi\u00ae m\u00e1s \u25bcDaklinza\u00ae, con amiodarona<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Riesgo de bradicardia severa y bloqueo cardiaco asociado a la administraci\u00f3n de \u25bcHarvoni\u00ae, y la combinaci\u00f3n de \u25bcSovaldi\u00ae m\u00e1s \u25bcDaklinza\u00ae, con amiodarona<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-271","post","type-post","status-publish","format-standard","hentry","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=271"}],"version-history":[{"count":1,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/271\/revisions"}],"predecessor-version":[{"id":272,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/271\/revisions\/272"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}